1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Personalizing Cancer Drugs Trends Industry

Global Personalizing Cancer Drugs Trends Industry

  • January 2014
  • -
  • Global Industry Analysts
  • -
  • 28 pages

The report illustrates that understanding of cancer is shifting from a pathology-oriented perspective to a molecular perception. Mechanisms responsible for driving cancer continue to emerge in diverse environments. In addition, the report presents an overview on the mechanism instrumental for causing some forms of breast cancer may also be responsible for promoting a subset of melanoma or brain cancer. The improved knowledge of cancer genetics is facilitating development of numerous drugs that target specific cancer cells. Cancer is one of the major chronic diseases worldwide and also the chief cause behind a huge number of fatalities. Each year, statistics post a larger figure than the previous year, indicating the rapidly growing incidence and prevalence of cancer. However, a similar pace of growth is not being reported in the area of development of drugs and therapies for treating cancers.

The report also predicts that the future holds immense promise for molecular analysis in the diagnosis and treatment of various types of cancer, clearing the path for personalized medicine towards becoming a common expression associated with cancer treatment. Continued advances in technology are expected to lead to application of molecular analysis at each and every step in the course of cancer, ultimately enabling designing of optimal therapies, with the potential of achieving the best possible outcome, for individual patients.

Table Of Contents

Global Personalizing Cancer Drugs Trends Industry


Personalized Medicine in Cancer Treatment - An Overview

Molecular Diagnosis and Personalized Medicine Fast Gaining Ground

Advances in Personalized Medicine in Cancer

Research for Developing Tools for Genetic Profile of Tumors

Role of Pharmacogenomics in Personalized Therapies for Cancer

Modern Personalized Medicine for Cancer - A Notch above Traditional Variant

Genomic, Proteomic, Epigenomic and Metabolomic Information to Aid Personalized Medicine in Cancer

Genomic Information for Improving Efficacy of Personalized Medicine in Cancer

Importance of Proteomic Information in Personalized Medicine for Cancer

Study of Human Epigenome Contributing to Personalized Medicine for Cancer

Metabolomics - The Latest Addition to Personalized Medicine Domain

Personalized Medicine in Diagnosis and Treatment of Breast Cancer


Growing Trend towards Personalized Medicine to Fuel the Market for Cancer Diagnostics

Progressing Personalized Medicine Cancer Drugs to Clinical Stage

Need for Personalized Therapy to Go Beyond Primary Cancers

Regional Differences in Cancer Causative Factors - A Major Hindrance in Development of Cancer Therapies

Personalized Medicine in Cancer - Issues to Address

Insurance Coverage for Personalized Medicine

Participation of Healthcare Providers Key for Success of Personalized Medicine

Elimination of Regulatory Hindrances a Must

Increasing Awareness among Public for Maximizing Benefit

Scientific Barriers to Address

Recent Progress in Research

ALK Gene Inhibitors Foray into Pediatric Personalized Medicine


Biomarkers for Cancer

Early Detection Biomarkers

Diagnostic Biomarkers

Prognostic Biomarkers

Predictive Biomarkers

Pharmacodynamic Biomarkers

Biomarkers - Diagnosis and Prediction of Common Cancers

Breast Cancer


Colon Cancer



Lung Cancer


An Introduction to Personalized Medicine

Uniqueness of DNA and Lifestyles Necessitate Personalized Medicine

Understanding Genetic Variations for Developing Better Drugs and Therapies

Molecular Analysis for Identification of Disease Sub-Groups in Polygenic Disorders

Key Benefits of Molecular Analysis of Diseases

Early Interventions and Enhanced Diagnoses

Improved Drug Development Efficiency

More Efficient Therapies

Personalized Medicine - Implications Involved

A Perfect Intellectual Property Rights System

Suitable Reimbursement Policies

Regulatory Reviews

Addressing Issues of Confidentiality, Privacy and Rights of Patients

Future Potential of Personalized Medicine


Cell Therapeutics, Inc. (USA)

F. Hoffmann-La Roche Ltd. (Switzerland)

H3 Biomedicine, Inc. (USA)


Roche Announces FDA Approval for Perjetaâ„¢

Roche Receives EU Consent for Zelboraf Cancer Drug

Roche Receives FDA Approval for Zelboraf Cancer Drug

Roche Obtains EU Approval for Tarceva


Pfizer Canada Launches XALKORI®

bioTheranostics Introduces New Line of “PRECIS” Biomarkers Series


AlacrisTheranostics Inks Pact with GlaxoSmithKline

4SC Discovery Obtains Grant for Developing New Personalized Cancer Drugs

Merrimack Enters into a Partnership with CTCA

Genomic Health Forms Strategic Alliance with OncoMed

Epizyme Enters into Partnership with Celgene for Advancing MLL Therapy

Abbott Expands Personalized Medicine Alliance with GSK

QIAGEN Inks Pact with Pfizer for Developing Companion Diagnostic

Blueprint Plans to Create Genomics-based Cancer Drugs

H3 Biomedicine Commences RandD Operations for Innovative Cancer Treatments

H3 Biomedicine Receives Research Funding from Eisai


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8 085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8 085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Opioid Market in the US

  • October 2016
    32 pages
  • Opioid  


    Infectious Dise...  

  • United States  



View report >

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.